

# Kyla A Mckay

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6740981/publications.pdf>

Version: 2024-02-01

34  
papers

1,288  
citations

393982

19  
h-index

377514

34  
g-index

35  
all docs

35  
docs citations

35  
times ranked

1777  
citing authors

#	ARTICLE	IF	CITATIONS
1	Health-related quality of life in multiple sclerosis. <i>Neurology</i> , 2016, 86, 1417-1424.	1.5	156
2	Psychiatric comorbidity is associated with disability progression in multiple sclerosis. <i>Neurology</i> , 2018, 90, e1316-e1323.	1.5	136
3	Factors associated with onset, relapses or progression in multiple sclerosis: A systematic review. <i>NeuroToxicology</i> , 2017, 61, 189-212.	1.4	83
4	Cholesterol and markers of cholesterol turnover in multiple sclerosis: relationship with disease outcomes. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 5, 53-65.	0.9	77
5	Comorbidity increases the risk of relapse in multiple sclerosis. <i>Neurology</i> , 2017, 89, 2455-2461.	1.5	77
6	Risk Factors Associated with the Onset of Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Systematic Review. <i>BioMed Research International</i> , 2015, 2015, 1-11.	0.9	76
7	Long-term disability progression of pediatric-onset multiple sclerosis. <i>Neurology</i> , 2019, 92, e2764-e2773.	1.5	69
8	Long-term Cognitive Outcomes in Patients With Pediatric-Onset vs Adult-Onset Multiple Sclerosis. <i>JAMA Neurology</i> , 2019, 76, 1028.	4.5	68
9	Disability worsening among persons with multiple sclerosis and depression. <i>Neurology</i> , 2019, 93, e2216-e2223.	1.5	63
10	Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study. <i>Multiple Sclerosis Journal</i> , 2017, 23, 588-596.	1.4	44
11	Physical activity and disability outcomes in multiple sclerosis: A systematic review (2011-2016). <i>Multiple Sclerosis and Related Disorders</i> , 2018, 20, 169-177.	0.9	43
12	Comorbidity is associated with pain-related activity limitations in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 470-476.	0.9	40
13	Fatigue and Comorbidities in Multiple Sclerosis. <i>International Journal of MS Care</i> , 2016, 18, 96-104.	0.4	38
14	Diagnoses of Depression and Anxiety Versus Current Symptoms and Quality of Life in Multiple Sclerosis. <i>International Journal of MS Care</i> , 2018, 20, 76-84.	0.4	35
15	A population-based study comparing multiple sclerosis clinic users and non-users in British Columbia, Canada. <i>European Journal of Neurology</i> , 2016, 23, 1093-1100.	1.7	29
16	Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: A study of the Swedish multiple sclerosis registry. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1051-1059.	1.4	29
17	Adverse health behaviours are associated with depression and anxiety in multiple sclerosis: A prospective multisite study. <i>Multiple Sclerosis Journal</i> , 2016, 22, 685-693.	1.4	27
18	Determinants of neurological disease: Synthesis of systematic reviews. <i>NeuroToxicology</i> , 2017, 61, 266-289.	1.4	22

#	ARTICLE	IF	CITATIONS
19	Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	22
20	Determinants of quality of life in pediatric- and adult-onset multiple sclerosis. <i>Neurology</i> , 2020, 94, e932-e941.	1.5	20
21	Military service and related risk factors for amyotrophic lateral sclerosis. <i>Acta Neurologica Scandinavica</i> , 2021, 143, 39-50.	1.0	19
22	Genetic variation associated with the occurrence and progression of neurological disorders. <i>NeuroToxicology</i> , 2017, 61, 243-264.	1.4	18
23	Comorbidities Are Associated with Altered Health Services Use in Multiple Sclerosis: A Prospective Cohort Study. <i>Neuroepidemiology</i> , 2018, 51, 1-10.	1.1	18
24	Long-term Socioeconomic Outcomes Associated With Pediatric-Onset Multiple Sclerosis. <i>JAMA Neurology</i> , 2021, 78, 478.	4.5	15
25	Familial risk of early- and late-onset multiple sclerosis: a Swedish nationwide study. <i>Journal of Neurology</i> , 2019, 266, 481-486.	1.8	13
26	Drug exposure and the risk of multiple sclerosis: A systematic review. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 133-139.	0.9	8
27	Reduction in Cognitive Processing Speed Surrounding Multiple Sclerosis Relapse. <i>Annals of Neurology</i> , 2022, 91, 417-423.	2.8	8
28	The systematic search for risk factors in multiple sclerosis. <i>Lancet Neurology</i> , The, 2015, 14, 237-238.	4.9	7
29	Disease-Modifying Therapies and Adherence in Multiple Sclerosis: Comparing Patient Self-Report with Pharmacy Records. <i>Neuroepidemiology</i> , 2017, 48, 124-130.	1.1	6
30	Cerebrospinal fluid markers in incident pediatric-onset multiple sclerosis: a nationwide study. <i>Scientific Reports</i> , 2021, 11, 18528.	1.6	5
31	Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden. <i>JAMA Network Open</i> , 2021, 4, e2136697.	2.8	5
32	Validating the diagnosis of multiple sclerosis using Swedish administrative data in Värmland County. <i>Acta Neurologica Scandinavica</i> , 2021, 144, 680-686.	1.0	4
33	Administrative data for observational research in multiple sclerosis: Opportunities and challenges. <i>Multiple Sclerosis Journal</i> , 2022, 28, 3-6.	1.4	2
34	Epidemiology of Multiple Sclerosis and Environmental Risk Factors. , 2021, , 137-153.		0